Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects

European Journal of Clinical Pharmacology

Volumn 54, Issue 9-10, 1998, Pages 707-714

  Bode Boger S M ^a   Boger R H ^a   Schubert, M ^a   Frolich J C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

2,3 Dinor 6 keto PGF(1 ); 2,3 Dinor TXB2; Platelet aggregation

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; PROSTACYCLIN; THROMBOXANE; THROMBOXANE A2;

ADULT; ARTICLE; BLEEDING; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; ASPIRIN; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; DOUBLE-BLIND METHOD; EPOPROSTENOL; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TABLETS, ENTERIC-COATED; THROMBOXANES;

EID: 0344177514     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050539     Document Type: Article

References (45)

1. Ali M, McDonald JWD, Thiessen JJ, Coates PE (1980) Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric coated aspirin. Stroke 11: 9-13
2. Antiplatelet Trialist's Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308: 81-106
3. Benedeck IH, Joshi AS, Pieniaszek HJ, King SYP, Kornhauser DM (1995) Variability in the pharmacokinetics and pharmucodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 35: 1181-1186
4. Bochner F, Lloyd J (1986) Is there an optimal dose and formulation of aspirin to prevent arterial thromboembolism in man? Clin Sci 71: 625-631
5. Bochner F, Williams DB, Morris PMA, Siebert DM, Lloyd JV (1988) Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 35: 287-294
6. Böger RH, Bode-Böger SM, Gutzki FM, Tsikas D, Weskott HP, Frölich JC (1993) Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. Clin Sci 84: 517-524
7. Böger RH, Bode-Böger SM, Schröder P, Frölich JC (1995) Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin. J Appl Physiol 78: 1832-1838
8. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325: 1137-1141
9. DeCaterina R, Gianessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. Am J Cardiol 55: 589-590
10. Dutch TIA Trial Study Group (1988) The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischaemic attacks or nondisabling stroke. Stroke 19: 512-517
11. FitzGerald GA, Brash AR, Flardeau P, Oates JA (1981) Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 68: 1272-1276
12. FitzGerald GA, Pedersen AK, Patrono C (1983a) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67: 1174-1177
13. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR (1983b) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71: 676-688
14. Force T, Milani R, Hibberd P, Lorenz R, Uedelhoven W, Learf A, weber P (1991) Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift: analysis of the effects of a combination of aspirin and n-3 fatty acids on the eicosanoid profile. Circulation 84: 2286-2293
15. Frölich JC, Wilson TW, Sweetman BJ, Smigel M, Nies AS, Carr K, Watson JT, Oates JA (1975) Urinary prostaglandins. Identification and origin. J Clin Invest 55: 763-770
16. Hanley SP, Bevan J, Cockbill SR, Heptinstall S (1982) A regimen for low-dose aspirin? Br Med J 285: 1299-1302
17. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ (1991) Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 32: 77-83
18. ISIS-2 Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet II: 349-360
19. Jaffe EA, Weksler BB (1979) Recovery of endothelial cell prostacyclin production after inhibition of low doses of aspirin. J Clin Invest 63: 532-535
20. Jimenez AH, Stubbs ME, Tofler GH, Winter K, Williams GH, Muller JE (1992) Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 69: 258-262
21. 1α excretion in healthy subjects. Thromb Res 45: 355-361
22. Knapp HR, Healy C, Lawson J, FitzGerald GA (1988) Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res 50: 377-386
23. Küster LJ, Frölich JC (1986) Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins 32: 415-423
24. Levy JH (1994) Aspirin and bleeding after coronary artery bypass grafting. Anesth Analg 79: 1-3
25. May JA, Heptinslall S, Cole AT, Hawkey CJ (1997) Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. Thromb Res 88: 183-192
26. Patrono C (1989) Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci 10: 453-458
27. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Cutella F, Davi G, Forni L (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 1177-1184
28. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA (1986) Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 77: 590-594
29. Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311: 1206-1211
30. Physicians' Health Study Research Group; Final report on the aspirin component of the ongoing physicians health study. N Engl J Med (1989) 321: 129-135
31. Prichard PJ, Kitchingman GK, Hawkey CJ (1989) Human gastric mucosal bleeding induced by low-dose aspirin, but not warfarin. Br Med J 298: 493-496
32. Ranke C, Creutzig A, Luska G, Wagner HH, Galanski M, BodeBöger SM, Frölich JC, Avenarius HJ, Hecker H, Alexander K (1993) Dosisabhängige Nebenwirkungen der Acetylsalicylsäuretherapie. Med Klin 88: 571-576
33. Rees Willett L, Carson JL, Strom BL (1994) Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Safety 10: 170-181
34. Reilly IAG, FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69: 180-186
35. Roderick PJ, Wilkes HC, Meade TW (1993) The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 35: 219-226
36. Rosenkranz B, Frölich JC (1985) Plasma concentrations and antiplatelet elfects after low dose asetylsalicylic acid. Prostaglandins Leukot Med 19: 289-300
37. Savon JJ, Allen ML, DiMarino AJ, Hermann GA, Krum RP (1995) Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol 90: 581-585
38. Schafer AI, Crawford DD, Gimbrone MA Jr (1984) Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 73: 1105-1112
39. Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K (1993) Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 54: 84-89
40. Stalnikowicz-Darvasi R (1995) Gastroinlestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. J Clin Gastroenterol 21: 13-16
41. Steering Committee of the Physician's Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physician's Health Study. N Engl J Med 321: 129-135
42. 2 and prostacyclin. Stroke 23: 1400-1403
43. UK-TIA Study Group (1991) The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiaty 54: 1044-1054
44. Vanags D, Rodgers SE, Lloyd JV, Bochner F (1990) The antiplatelet effect of daily low dose enteric-coated aspirin in man. A time course of onset and recovery. Thromb Res 59: 995-1005
45. Vesterqvist O (1986) Rapid recovery of in vivo proslacyclin formation after inhibition by aspirin. Eur J Clin Pharmacol 30: 69-73